COVID-19 trials registries data warehouse

 Return to trial list

Trial - JPRN-jRCTs071210011


Column Value
Trial registration number JPRN-jRCTs071210011
Full text link
Last imported at : April 23, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

First author
Last imported at : April 23, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Kazuko Yamamoto

Contact
Last imported at : April 23, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

kazukomd@nagasaki-u.ac.jp

Registration date
Last imported at : April 23, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

2021-04-13

Recruitment status
Last imported at : June 30, 2022, 4:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Not recruiting

Study design
Last imported at : April 23, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

RCT

Allocation
Last imported at : April 23, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Randomized

Design
Last imported at : April 23, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Parallel

Masking
Last imported at : April 23, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Open label

Center
Last imported at : April 23, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

multi-center

Study aim
Last imported at : April 23, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Treatment

Inclusion criteria
Last imported at : April 23, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Patients who meet all of the following criteria are included in this study:1. Patients who were detected SARS-CoV-2 in PCR tests or LAMP method within 3 days before the informed consent.2. Patients with pneumonia image by routine chest radiography or chest CT.3. Japanese patients who are aged of 20 years or older.4. Patients who give their written consent form to participate in the study.

Exclusion criteria
Last imported at : June 17, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Patients who fall into any of the following criteria are excluded from participating in the study:1. Patients who has the symptom 8 days or longer.2. Patients who are treated by macrolide antimicrobial agents. 3. Patients who are treated by steroids (except inhalants) or immunosuppressive agents4. Patients who are diagnosed with influenza.5. Patients whose SPO2 is less than or equal to 93%. (at room)6. Patients with hepatic dysfunction. (AST / ALT more than 5 times of the facility standard value or Child-Pugh B/C)7. Patients with renal dysfunction. (Cre more than twice of the facility standard value and eGFR<30ml/min)8. Patients whose peripheral blood neutrophils are less than 1,000/uL.9. Patients who have history of hypersensitivity to macrolide antimicrobial agents.10. Patients who are pregnant, breastfeeding.11. Patients who have been vaccinated against COVID-19 in the past.12. Patients with other conditions that the investigator thinks inappropriate to participate in the study.

Number of arms
Last imported at : April 23, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

3

Funding
Last imported at : April 23, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Mukae Hiroshi

Inclusion age min
Last imported at : April 23, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

20

Inclusion age max
Last imported at : April 23, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

100

Countries
Last imported at : April 23, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Japan

Type of patients
Last imported at : April 23, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Mild/moderate disease at enrollment

Severity scale
Last imported at : April 23, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

2: Mild/moderate disease at enrollment

Total sample size
Last imported at : April 23, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

60

primary outcome
Last imported at : April 23, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Days required to improve clinical symptoms by 50% or more from baseline (at registration)

Notes
Last imported at : April 23, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Phase
Last imported at : April 23, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Not reported

Arms
Last imported at : April 23, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

[{"arm_notes": "400mg/day ", "treatment_id": 292, "treatment_name": "Clarithromycin", "treatment_type": "Antibiotics", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "800mg/day ", "treatment_id": 292, "treatment_name": "Clarithromycin", "treatment_type": "Antibiotics", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]